CD19 and breast cancer: However, as mentioned above, CD19+ B cells were significantly downregulated in nivolumab-treated CH401MAP-immunized BC-M spleen and BM, whereas B cell proportions were not changed following nivolumab injection in HD-M (Fig. 5C).